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The distal segment of an injured nerve normally undergoes Wal-
lerian degeneration within 24–48 hours1. Axon death in diverse
neurodegenerative diseases follows the same final pathway. The
earliest observable events, disruption of the cytoskeleton and
blebbing of the axolemma, occur within the axon itself, whereas
later stages also involve the reaction of other cell types, such as
Schwann cells and macrophages. It is not known how Wallerian
degeneration is initiated, but the mechanism is clearly distinct
from neuronal cell body degeneration2,3.
Remarkably, central and peripheral nervous system axons in
the slow Wallerian degeneration mutant mouse, C57BL/WldS,
survive several weeks after transection4–6. The neuroprotective
phenotype is dominant5 and intrinsic to the axon2,7,8. Thus, an
unknown protective factor should exist in WldS axons even before
nerve transection, as the protected distal segment of axon is iso-
lated from sites of protein translation. The existence of the puta-
tive regulatory molecule suggests that Wallerian degeneration is
not a passive process, as previously thought, but an active one
that removes damaged axons8. How this degenerative process is
prevented in healthy axons, and thus the nature of the process
itself, should follow from the identification of the Wld gene.
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Axons and their synapses distal to an injury undergo rapid Wallerian degeneration, but axons in the
C57BL/WldS mouse are protected. The degenerative and protective mechanisms are unknown. We
identified the protective gene, which encodes an N-terminal fragment of ubiquitination factor E4B
(Ube4b) fused to nicotinamide mononucleotide adenylyltransferase (Nmnat), and showed that it
confers a dose-dependent block of Wallerian degeneration. Transected distal axons survived for two
weeks, and neuromuscular junctions were also protected. Surprisingly, the Wld protein was located
predominantly in the nucleus, indicating an indirect protective mechanism. Nmnat enzyme activity,
but not NAD+ content, was increased fourfold in WldS tissues. Thus, axon protection is likely to be
mediated by altered ubiquitination or pyridine nucleotide metabolism.
Wallerian degeneration has a prominent causative role in a spec-
trum of human neuropathologies. Axon loss occurs not only in
traumatic disorders such as spinal cord injury9, but is an early event
in numerous neurological disorders of diverse etiology, such as amy-
otrophic lateral sclerosis10, multiple sclerosis11 and toxic neuropa-
thy12. The WldS mutation protects also from vincristine toxicity13
and its potential for protection of axons in diverse neurological dis-
eases is an area of considerable current interest. Protection of neu-
ronal cell bodies often fails to prevent neurological disease14,15, so it
is also important to find ways to protect axons. Thus, the Wld gene
may open a new avenue for therapeutic strategies.
An 85-kb tandem triplication16 has been characterized with-
in the WldS region on distal mouse chromosome 4 (ref. 17). This
led to the discovery of a chimeric gene containing the 5´ end of
Ube4b and a gene of previously unknown function, D4Cole1e18.
Both parent proteins are also expressed in WldS mice. The human
homolog of D4Cole1e (F.S. Fernando, unpublished data) is iden-
tical to human NMNAT19, a key enzyme in the synthetic path-
way of NAD+ (ref. 20). Although the chimeric gene is the most
plausible candidate for Wld, the triplication also directly affects
retinol binding protein 7 (Rbp7) and could exert a position effect
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β-actin promoter. Four transgenic lines (4830,
4836, 4839 and 4858) expressed the protein from
multi-copy integrations. The transgene expression
level increased in the order 4839 < 4830 ≈ 4858 <
WldS ≈ 4836 (Fig. 3). Line 4858, whose expression
level and phenotype was similar to line 4830, is not
discussed further. Like spontaneous WldS mice,
transgenic mice up to at least one year old showed
no unusual overt phenotype.
Structural preservation of transected axons
First we tested the structural preservation of
axons following unilateral sciatic nerve transec-
tion, analyzing a nerve segment 2–4 mm distal to
the lesion after 3–5 days. Electron microscopy
revealed that almost all axons in line 4836
homozygotes, separated from their cell bodies for
five days, contained fully preserved cytoskeleton
(Fig. 1 and Supplementary Fig. 1, available on the
Nature Neuroscience web site), thus successfully
reproducing the WldS phenotype. In contrast, all myelinated
and unmyelinated wild-type axons showed clear signs of degen-
eration. Line 4830 axons were partially protected in accordance
with the lower transgene expression level in this line (Fig. 3a)
and line 4839 homozygotes also showed partial protection after
Fig. 1. Preserved axon ultrastructure in distal sciatic
nerve 5 days after transection. Electron micrographs
(3,400×) of transverse thin sections of lesioned sciatic
nerve 2–4 mm distal to the lesion site after 5 days. (a)
Wild-type, (b) 4836 homozygote, (c) 4830 homozygote
(d) WldS homozygote. Insets, 20,000× magnifications of
axons marked by asterisk (top inset) and ‘#’ (bottom
inset) from main images. 
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on nearby genes. Indeed, mutation of the human homolog of
one neighboring gene, kinesin family 1b (Kif1b)21, causes axon
loss in Charcot-Marie-Tooth disease type 2A22.
To test the hypothesis that the Ube4b/Nmnat chimeric gene
confers the slow Wallerian degeneration phenotype, we expressed
it in transgenic mice. The WldS phenotype was reproduced fully
in one line and partially in other lines according to transgene
expression level, thus proving that the chimeric gene is the Wld
gene. We detected Wld protein in nuclei of neurons but neither in
axons nor in Schwann cells, implicating the existence of down-
stream factor(s) that mediate the protective effect. Further, we
report that the Wld protein showed Nmnat enzyme activity and
acted in a strongly dose-dependent manner.
RESULTS
Generation of transgenic mice
To test the role of the Ube4b/Nmnat chimeric gene, we generated




Fig. 2. Physiological and morphological evidence for preservation of
axons and neuromuscular junctions. Intracellular recordings (a, b), vital
staining (c, d) and immunostaining (e, f) in isolated transgenic muscles.
(a) Homozygous 4836 FDB, 3 days after axotomy; (b) hemizygous 4836
FDB after 2 days. (c, d) Lumbrical muscles from 4836 hemizygote, 
3 days after axotomy (c); 4836 homozygote, 5 days after axotomy (d)
vitally stained with FM1-43, which indicates intact synaptic transmission
mechanisms, together with TRITC-α-bungarotoxin staining of acetyl-
choline receptors. (e, f) Immunostaining for neurofilament/SV2 (FITC)
and TRITC-α-bungarotoxin. (e) 4836 homozygous lumbrical muscle, 
5 days after axotomy, showing occupied endplates and some axon
swelling. (f) Confocal stereo pair of 5-day axotomized 4836 homozy-
gous lumbrical muscle showing almost fully occupied endplates (left and
right), partially occupied (second right) and junction with only a slender
axonal filament tipped by a ‘retraction bulb’ (second left). Scale bar, 
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Fig. 3. Dose-dependence of axon protection by the Wld gene. 
(a) Top, western blot showing the extent of 200-kD neurofilament
protein degradation in distal sciatic nerve 3 days after transection 
(5 days for 4836 and WldS homozygotes). Complete preservation of
NF-200 in uncut contralateral nerve (lane 1) indicated degradation
occurred only in vivo. Middle, western blot showing the expression
level of the Wld protein in brain homogenates (detected by N70 anti-
serum). Bottom, same western blot probed with control monoclonal
antibody β-tub 2.1 against β-tubulin. (b) Percentage of intact myeli-
nated axons 2–4 mm distal to a sciatic nerve lesion. Preserved axons
were counted using light microscopy in nerve segments immediately
proximal to those used in (a). Counts of 93–99% in uncut contralat-
eral nerves confirmed that observed degeneration occurred in vivo. 
n indicates total number of nerves counted. Mean ± s.e.m. of the mid-
dle three scores when n is odd; mean ± s.e.m. of the middle four
when n is even. (c) Axon preservation as a function of the expression
level of Wld protein. Axon preservation after 3 (black circle), 5
(white square) and 14 (cross) days as in (b); means ± s.e.m. where 
n > 1. Wld protein expression level is the signal quantified from (a),
standardized against β-tubulin and expressed as a percentage of the
expression in WldS homozygotes.
Thus, motor nerve conduction, synaptic transmission, vesi-
cle recycling and motor nerve terminal morphology were pre-
served in a dose-dependent manner, with line 4836 showing a
level of protection similar to WldS. Axons evidently persisted
longer than functional motor nerve terminals, supporting the
hypothesis that synaptic degeneration, at least in WldS mice, dif-
fers from that of axons and neuronal cell bodies25.
Protection depends on Wld protein expression level
The above experiments suggested that the degree of protection
depends on the expression level of Wld protein. This was sur-
prising because heterozygous WldS axons at short survival times
degenerate only slightly faster than those of homozygotes5. We
quantified Wld protein expression in each mutant strain to deter-
mine the level required to preserve cytoskeletal protein and axon
structure for 3–5 days (Fig. 3). At lower expression levels, both
measures of axon preservation indicated a strong dose-depen-
dence. Axon counts at 3 days differed significantly between hem-
izygous 4836 and hemizygous 4830 mice (p < 0.001). Significant
differences between homozygotes and hemizygotes of a single
line (p < 0.01 for 4830; p < 0.001 for 4839) indicated that this is
not a line-specific silencing effect26. Line 4839 hemizygotes were
even indistinguishable from wild-type mice in neurofilament
western blotting (NF-200 band, Fig. 3a), light microscopy 
(Fig. 3b) and electron microscopy (data not shown), despite
expressing a small amount of the Wld protein (Fig. 3a). Thus, it
is necessary for expression of Wld to reach a threshold level to
exert a significant protective effect.
To investigate whether the protective effect of Wld protein
plateaus at higher expression levels, and to test axon protection in
articles




three days (Fig. 3a). Presence of the WldS phenotype in inde-
pendent lines confirms that it is caused by the transgene rather
than any integration effect. Thus, Ube4b/Nmnat is the Wld
gene, and it protects both sensory and motor axons in 
WldS and transgenic mutants. No alteration to Rbp7, Kif1b 
or any other gene is required to reproduce the phenotype 
of WldS mice.
Functionally competent motor axons and synapses
Next we tested whether axons were functionally as well as struc-
turally preserved. Nerve–muscle preparations of flexor digito-
rum brevis (FDB) were isolated and stimulated 2–5 days after
lesion. Axotomized wild-type muscles showed no response at
these time points. In axotomized transgenics, however, as in the
WldS mutant23, conduction of action potentials and synaptic
transmission at neuromuscular junctions persisted for at least
three days (Fig. 2). In a homozygous 4836 mouse, 80% (12/15) of
muscle fibers responded to nerve stimulation three days after sci-
atic nerve section (for example, Fig. 2a). In another 4836
homozygote, functional innervation even after 5 days was indi-
cated by 73% (22/30) of FDB muscle fibers showing spontaneous
miniature endplate potentials (MEPP) and some responding to
nerve stimulation (data not shown). Weaker, and sometimes
more variable, responses indicating low quantal content were
observed both in line 4836 hemizygotes (Fig. 2b) and homozy-
gous 4830 mice. In the latter, 50% (12/24) and 30% (8/25) of
fibers from two mice responded to stimulation two days after
lesion. These weaker responses are in accord with the lower
expression levels of the Wld protein (see below).
Axotomized 4836 nerve terminals also recycled synaptic vesi-
cles, visualized by activity-dependent staining with the styryl dye
FM1-43, both upon incubating lumbrical muscles in a depolar-
izing solution (Fig. 2c and d) and upon stimulation of the distal
stump of axotomized tibial nerve. Preservation of pre- and post-
synaptic structures was confirmed using antibodies against
NF165/SV2 and TRITC-α-bungarotoxin respectively (Fig. 2e and
f). In two line 4836 homozygotes, 87–93% of endplates (n = 154
and 164) were occupied or partially occupied (8%) by nerve ter-
minals 5 days after axotomy, similar to WldS mice23,24. Fewer than
50% (n = 187 and 210) were occupied in two 4836 hemizygotes
after 3 days, and fewer still in 4830 homozygotes, again reflect-
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transgenic mice under still more stringent conditions, we extend-
ed these studies to post-lesion times of 10–14 days. Fourteen days
after transection, protection of axons in line 4836 homozygotes
(69–73%) was as strong as that in WldS homozygotes (73–78%;
Figs. 3c and 4), again indicating full reproduction of the WldS phe-
notype. Protection in line 4836 hemizygotes, however, was con-
siderably weaker (35% after 10 days and only 7% after 14 days).
Thus, the extent of axon protection differed far more between
4836 homo- and hemizygotes after 14 days than after 3–5 days,
indicating that dose-dependence still operates at higher Wld
expression levels. It follows that if Wld protein expression could
be raised still further, an even stronger protective effect than in
WldS and line 4836 mice could be achieved.
Wld is a predominantly nuclear protein
To determine whether the Wld protein could itself be the pro-
tective factor in axons, we determined its intracellular loca-
Fig. 5. The intracellular location of the Wld protein. (a) Presence of
the Wld protein in neuron nuclei of isocortex and (b) its absence from
C57BL/6J control tissue. Red, anti-N70 antibody, which detects Wld
and Ube4b. Green, anti-MAP2 antibody markedly outlining neuronal
cell bodies. (c) Absence of Wld protein (red) in astrocytes (arrows,
main picture). Cytoplasmic staining in ependymal cells (central chan-
nel) of WldS thoracic spinal cord could be Ube4b. Inset, absence in
astrocytes and endothelial cells (arrow) of WldS isocortex. Green, anti-
GFAP. Blue, Hoechst Dye nuclear counterstain. (d–f) Confocal images
of triangularis sterni muscle preparations immunostained with anti-
N70 antibody (green) and motor endplates counterstained with
TRITC α-bungarotoxin (red). (d) 4836 homozygote, (e) WldS, 
(f) C57BL/6J. (g–i) Motor neurons in thoracic spinal cord of both WldS
(g) and 4836 (h) expressed the Wld protein (red) in their nuclei,
whereas those of C57BL/6J (i) did not. Cytoplasmic signals may be
Ube4b or low level Wld protein. Counterstain, neurofilament (green).
(j–l) Red channel (Wld protein plus Ube4b) images corresponding to
(g–i). Scale bars, 5 µm (a, b), 10 µm (c), 50 µm (d–l).
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tion. An antiserum labeling the N-terminal 70 amino acids of
Wld protein and Ube4b detected mainly a punctate nuclear pat-
tern in WldS and transgenic neurons (Fig. 5a, c, g and h) and this
signal was absent in wild-type neurons (Fig. 5b and i). There was
no detectable signal either in motor axon terminals (Fig. 5d–f),
which can be preserved by the Wld gene (Fig. 2e and f), or in sci-
atic nerve axons (Supplementary Fig. 2, available on the Nature
Neuroscience web site). Swollen endbulbs of 24-hour transected
central and peripheral nervous system axons, which accumulate
other axonal proteins, also lacked Wld protein signal (data not
shown). In addition, the antibody weakly labeled the normal
Ube4b protein in cytoplasm of wild-type mice, so additional
labeling of any small amount of cytoplasmic Wld protein might
not be distinguishable.
Although the WldS phenotype is intrinsic to neurons2,7,8, Wld
protein was also detected as a punctate nuclear stain in other cell
types in both WldS and transgenic mice (Fig. 5d and e). There
was no sign of Wld protein in glial cells (Fig. 5c–e), although pre-
vious RT-PCR (reverse transcription-polymerase chain reaction)
data indicate there may be a small amount in Schwann cells18. It





Fig. 4. Axon protection 10–14 days after transection. (a) Western blot
showing the extent of 200-kD neurofilament protein degradation in dis-
tal sciatic nerve 10–14 days after transection. Lane 1, 4836 homozygote
after 14 days; lane 2, WldS homozygote after 14 days; lane 3, 4836 hem-
izygote after 14 days; lane 4, 4836 hemizygote after 10 days; lane 5,
C57BL/6J after 12 days; lane 6, C57BL/6J unlesioned. (b–e) Light micro-
scopic images (scale bar, 10 µm) of distal sciatic nerves following tran-
section at a more proximal site 10–14 days earlier. (b) 4836
homozygote after 14 days (corresponding intact axon count, 73%), 
(c) WldS homozygote after 14 days (73%), (d) 4836 hemizygote after 
10 days (35%), (e) C57BL/6J after 12 days (0%). Electron microscopy
(data not shown) indicated that cytoskeleton and myelin was preserved
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to protect axons, but it is possible that the Wld protein confers
as yet unknown properties on other cell types. For example, the
delayed response of WldS muscles to denervation could have an
intrinsic component27. We conclude that the Wld protein is pre-
dominantly located in the nucleus; thus, other factor(s) are like-
ly to mediate the protective effect on axons.
The Wld protein has Nmnat enzyme activity
Sequence alignment with human NMNAT indicated that
nucleotides 282–1140 of Wld span the entire Nmnat open read-
ing frame. To detect any intrinsic Nmnat enzyme activity, we
expressed protein recombinantly and measured the enzyme activ-
ity of the bacterial lysate. The observed specific activity for Nmnat
(0.96 U/mg) was comparable with that of a bacterial lysate con-
taining recombinant human NMNAT (1.74 U/mg)19. To deter-
mine whether there is a corresponding increase in Nmnat activity
in WldS mice, we studied Nmnat activity in brain homogenates
and found a fourfold increase in WldS brain compared to
C57BL/6J (p < 0.05; Fig. 6a). The total content of NAD+, how-
ever, was not significantly altered (p = 0.2; Fig. 6b). Therefore,
the Wld protein confers an increase in Nmnat activity without
altering the steady-state level of NAD+.
DISCUSSION
We showed that the Ube4b/Nmnat chimeric gene is neces-
sary and sufficient to protect injured axons for two weeks. We
conclude that the Ube4b/Nmnat chimeric gene is the Wld gene,
which encodes a unique neuroprotective factor for axons. It is
important now to determine whether protection requires
Ube4b sequences, Nmnat sequences, or both. The yeast
homolog of Ube4b is required to multi-ubiquitinate proteins30
and a direct link between ubiquitination and axon degenera-
tion comes from the Uch-l1 mutation in gracile axonal dystro-
phy31. However, the Wld protein contains only 70 of 1,173
amino acids from Ube4b, and these are absent from the yeast
homolog. They are therefore unlikely to confer multi-ubiqui-
tination activity but may have a related role. The protective
mechanism may be linked to the nuclear location of the Wld
protein and perhaps to the non-homogeneous intranuclear
distribution. Possibilities include sequestering of ubiquitina-
tion factors by protein–protein interactions and ubiquitina-
tion within the nucleus altering transcription factor stability
or RNA processing, leading to an axon effect mediated by
unknown proteins. Regulated nuclear transport of other ubiq-
uitination factors can control ubiquitin-mediated degradation
of nuclear substrates32. However, any Wld protein in the axon
below the detection level of immunostaining could still have a
direct protective role.
Nmnat is a nuclear protein and the only known mammalian
enzyme catalyzing the reaction NMN + ATP → NAD+ + PPi 
(ref. 20), a reaction generally assumed not to be at equilibrium
because of the constitutive action of pyrophosphatases. Thus, the
increase in Nmnat activity in WldS should increase NAD+ syn-
thesis, and the maintenance of normal steady-state levels sug-
gests that the putative additional NAD+ is metabolized. The
product of a compensatory reaction could itself be involved in
axon protection. For example, poly-ADP ribosylation uses NAD+,
influencing protein activity and cellular NAD+ and ATP content,
especially in response to stress33,34. Mild activation of PARP with-
out NAD+ depletion can be neuroprotective35. Another metabo-
lite, NADPH, is a coenzyme for nitric oxide synthase, an enzyme
linked to axon damage36, and synthesis of the signaling molecule
cyclic ADP ribose from NAD+ regulates calcium release from
intracellular stores37, potentially influencing calcium activated
proteases in Wallerian degeneration.
Both spontaneous and transgenic WldS mice could be used to
investigate the function of each parent gene. We already show that
overexpression of Nmnat activity causes no overt phenotype, and
report an in vivo mutation of a mammalian E4 ubiquitination fac-
tor. Despite the critical role played by the ubiquitin-proteasome
pathway in neurological disease and many other processes, we
know remarkably little about the function of such proteins.
Identification of the Wld gene facilitates studies to deter-
mine whether it protects axons in clinically relevant situations.
The WldS mutation is already known to protect neuronal
processes in vitro from the toxic effects of vincristine13, indi-
cating that traumatic and toxic axon death share a common
final pathway. Current studies indicate that distal axon loss in
myelin protein zero knockout mutants38 is rescued by WldS
(M. Samsam and R. Martini, unpublished data), and that WldS
protects in a mouse model of motoneuron disease (A. Ferri and
A.C. Kato, unpublished data). Studies of WldS in diverse neu-
rological diseases is facilitated by our identification of the Wld
gene and by recent protocols for tracking the inheritance of
WldS in crosses with neurological disease mutants39. Models of
common and complex neurological disorders such as multiple
sclerosis and diabetic neuropathy can now be investigated
through the development of viral vectors for Wld and genera-
tion of transgenic WldS rats. Mutational analysis in human neu-
rological disorders with a homologous chromosomal location,
such as hereditary Parkinsonism40, also becomes possible.
Delayed Wallerian degeneration also alters the glial response to
injury, as in a mouse model of spinal cord injury, where it delays
inflammatory cell and astrocytic responses9,41. It may be that
this information could be used to optimize tissue destruction
and repair processes.
We conclude that the Wld gene is a chimera of Ube4b and
Nmnat encoding a predominantly nuclear protein in neurons,
and we propose that other factors may mediate the protective
effect on the axon. Axon protection is strongly dose-dependent
and pyridine nucleotide metabolism is altered in the WldS mouse.
These findings open the way to a molecular understanding of
Wallerian degeneration and to much-needed neuroprotective
strategies that target not only the cell body, but also the axons
and synaptic terminals.
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Fig. 6. NAD+ metabolism in WldS brain. (a) Increased Nmnat activity
and (b) unaltered NAD+ content in WldS brain. Bar charts show Nmnat
specific activity and NAD+ content in homogenates of fresh brain from
homozygous WldS and C57BL/6J mice. Means and standard error are
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METHODS
Generation of transgenic mice. Ube4b/Nmnat cDNA was RT-PCR
amplified from WldS brain using Platinum Pfx polymerase (Life Tech-
nologies, Karlsruhe, Germany) and cloned downstream of the β-actin
promoter in pHβAPr-1 (ref. 42; Supplementary Fig. 3). Wld protein
was thus expressed in neurons, where it has an intrinsic effect2,7,8, and
other cell types, where WldS mice also express it (Fig. 5). A 6-kb frag-
ment containing promoter, cDNA and polyadenylation signal was
released using NdeI and EcoRI and gel-purified using QIAquick extrac-
tion (Qiagen, Hilden, Germany). Pronuclear injection into CBA X C57
F1 single-cell embryos (G. Kollias, Vari, Greece) resulted in nine
founders from 62 pups.
Genotyping of transgenic mice. DNA was prepared from a 5-mm tail
biopsy using the Nucleon HT kit (Amersham Pharmacia, Freiburg,
Germany). The 1.1-kb transgene coding region was detected using
alkaline Southern blotting of a BamHI/HindIII double digest on
Hybond N+ (Amersham Pharmacia) and hybridization with a corre-
sponding 32P-labeled probe.
Sciatic nerve lesion. Six- to eleven-week-old mice were anesthetized
intraperitoneally with Ketanest (100 mg/kg; Bayer, Leverkusen, Germany)
and Rompun (5 mg/kg; Parke Davis/Pfizer, Karlsruhe, Germany). Right
sciatic nerves (upper thigh) were transected and the wounds were closed
with single sutures. Two to fourteen days later, mice were killed, the
swollen first 2 mm of the distal nerve was discarded, the next 2 mm was
used for light and electron microscopy, and a segment 4–10 mm distal
to the lesion site was used in western blotting. Further distal nerves and
muscles were used for electrophysiology.
Light and electron microscopy. Nerve segments were fixed for 1–3 days
in fresh half-strength Karnovsky’s fixation (4% paraformaldehyde, 2%
glutaraldehyde in 0.1 M sodium cacodylate, pH 7.3; ref. 43), extensively
buffer-rinsed and osmicated for 4 h with 1% OsO4 in 0.1 M cacodylate.
Samples were taken through a graded ethanol series including a uranylic
acetate en bloc staining step overnight in 70% ethanol. Before infiltra-
tion with Araldite Cy212 epoxy resin (Serva, Heidelberg, Germany),
propylene oxide was used as intermedium. Tissue blocks were cured for
60 h at 60°C. Semithin (0.5 µm) and thin (60 nm) cross-sections were
taken on a Reichert Ultracut UCT ultramicrotome. Semithin sections
for light microscopy were stained with methylene blue and thin sections,
with 1% aqueous uranylic acetate (20 min), and sections were counter-
stained with Reynold’s lead citrate (7 min)44. Thin sections were mount-
ed on 150 mesh Formvar coated copper grids and examined with a Zeiss
EM 902 electron microscope at 80 kV acceleration voltage.
Neuromuscular junction electrophysiology and morphology. FDB and
lumbrical muscles and contralateral controls were removed in Cologne
and placed in cold physiological saline (137 mM Na+, 4 mM K+, 2 mM
Ca2+, 1 mM Mg2+, 147 mM Cl–, 5 mM glucose, 5 mM HEPES, 
pH 7.2–7.4, equilibrated with air or 100% oxygen). Electrophysiological
experiments were done later the same day in Edinburgh, following trans-
fer to a medium containing similar concentrations of Na+, K+, Ca2+ and
Mg2+, plus 23 mM HCO3
–, 2 mM H2PO4
–, equilibrated with 95% O2/5%
CO2. MEPPs and evoked synaptic responses to tibial nerve stimulation
(EPPs) were recorded from FDB using an intracellular glass microelec-
trode and analyzed using WinWCP software45 (J. Dempster, University of
Strathclyde). Recycled synaptic vesicles of motor nerve terminals were
stained in lumbrical muscles using FM1-43 (Molecular Probes, Leiden,
Netherlands) with 20 Hz nerve stimulation or depolarizing physiological
solutions, and acetylcholine receptors subsequently stained with TRITC-
α-bungarotoxin (Molecular Probes)46,47. Endplates and terminals were
examined in a Nikon fluorescence microscope (Kingston-upon-Thames,
UK) using respectively a standard rhodamine filter cube and a customized
cube with a 435 nm excitation filter, 455 nm dichroic mirror and a 
10 nm bandpass 515 nm emission filter46.
Conventional immunocytochemical and fluorescent bungarotoxin
probes were used for structural analysis. Muscle preparations, fixed for 60
min in 0.1 M PBS, 4% paraformaldehyde, were incubated in TRITC-α-
bungarotoxin (5 µg/ml; 30 min) followed by overnight primary antibody
(1:200 monoclonal anti-165 kDa neurofilament plus anti-synaptic vesi-
cle antigen SV2, Developmental Studies Hybridoma Bank, University of
Iowa; or affinity purified rabbit polyclonal N70; see below). Secondary
antibodies (1:200 dilution; 4 h) were FITC-conjugated sheep-anti-mouse
IgG or anti-rabbit IgG (Diagnostics Scotland). Preparations were mount-
ed in Vektashield (Vector Labs, Burlingame, California) and viewed in a
fluorescence microscope using a Leitz 50× water immersion objective
lens (NA 1.00; Wetzlar, Germany). Most images were captured with a
Hamamatsu C5810 chilled color CCD camera and acquired using Open-
lab software (Improvision, Coventry, UK). Confocal images were
obtained using a BioRad Radiance 2000 system (Hemel Hempstead, UK).
Western blotting. We analyzed Wld protein expression level in mouse
brains homogenized in two volumes of 20 mM HEPES (pH 7.5), 0.2 M
CaCl2, 0.2 M MgSO4, 1 ml/20 g tissue protease inhibitor cocktail (Sigma,
Taufkirchen, Germany) and 1 mg/ml DNase (Sigma). Cytoskeletal protein
preservation was determined in lesioned sciatic nerves homogenized in 20
volumes of this buffer. Proteins were separated using standard SDS-PAGE
and semi-dry blotted onto nitrocellulose. Loading and transfer were
checked using Ponceau S (Sigma) and Coomassie Blue. Primary anti-
bodies were applied (overnight, 4°C) followed by horseradish peroxi-
dase-coupled secondary antibody (1 h, room temperature;
goat-anti-mouse 1:3,000, goat-anti-rabbit 1:5,000; Dianova, Hamburg,
Germany) and detection using enhanced chemiluminescence (Amer-
sham Pharmacia). Chimeric protein expression was quantified using
affinity-purified N70 antibody (below) and β-tub 2.1 (Sigma) control
and Quantity One software (BioRad). Cytoskeletal protein degradation
was analyzed using phosphate-independent monoclonal N52 (1:2,000;
Sigma) against heavy neurofilament protein.
Morphological quantification of axon preservation. We counted 500-
1500 myelinated axons in randomly chosen fields 2–4 mm distal to a sci-
atic nerve lesion in transverse semithin sections on a Zeiss Axiophot
microscope (Göttingen, Germany) coupled to a digital camera. Survival
criteria were normal myelin sheaths, uniform axoplasm and intact mito-
chondria, supported by electron microscopy spotchecks. Scoring was
documented with Meta Imaging software (Universal Imaging Corpora-
tion, Downingtown, Pennsylvania). Standard errors of the mean and t-
tests were calculated using SPSS for Windows 10.0.
Cloning and expression of recombinant proteins. Constructs were gen-
erated to express in bacteria the N-terminal 70 amino acids (N70) of the
chimeric protein and full-length chimeric protein. Inserts were PCR-
amplified from transgene construct using Pfx polymerase (Life Tech-
nologies). Primers for N70 were5´-GACTAGCTAGCATGGAGGAGCTGA
GCGCTGAC-3´ and 5´-ATCCGCTCGAGCTAGTCTGCTGCACCTATG
GGGGA-3´.
For full-length chimeric cDNA, the second primer was replaced by 5´-
CGCCTCGAGTCACAGAGTGGAATGGTTGTGC-3´.
Products were ligated into NheI/XhoI double-digested pET-28b (+) vec-
tor (Novagen, Schwalbach, Germany) and transformed into XL-10 Gold
(Stratagene, Amsterdam, Netherlands). Plasmids isolated using the Plasmid
Mini Kit (Qiagen) were retransformed into BL21 (DE3) (Novagen). Pro-
tein expression was induced with 1 mM IPTG for 3 h at OD600 = 0.8. For
analysis of Nmnat activity, cells were lysed by sonication.
Generation of polyclonal antisera. The N70 bacterial pellet was resus-
pended in native binding buffer (20 mM sodium phosphate, 500 mM
sodium chloride pH 7.8,100 µg/ml egg white lysozyme), sonicated on
ice (6 × 15 s with 15-s intervals) and centrifuged (3,000 g, 15 min). N70
was purified using a ProBond column (Invitrogen, Groningen, Nether-
lands) and concentrated using a YM-3 Centricon centrifugal filter (Mil-
lipore, Bedford, Massachusetts). Antisera were raised by intradermal
immunization of two SPF-rabbits by Eurogentec (Seraing, Belgium) with
boosts at days 14, 28 and 56, and a final bleed at 80 days.
For affinity purification 500 µg N70 protein bound to ProBond resin
(2 ml wet volume) was blocked with 5% (w/v) dried skimmed milk pow-
der plus 1% (w/v) BSA in native binding buffer. Resin was incubated
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bed volumes binding buffer. Specific antibodies, binding only Wld pro-
tein and Ube4b, were eluted with 100 mM ethanolamine (pH 11.5), neu-
tralized with 1.5 M Tris and dialyzed against PBS.
Immunocytochemistry of spinal cord, nerves and brain. Perfusion-
fixed tissues were fixed for a further four hours in 4% paraformalde-
hyde, 0.1 M PBS before embedding in paraffin. Paraffin sections on
poly-L-lysine coated slides were dewaxed, washed in PBS, rinsed in cit-
rate buffer overnight (60°C) and incubated with 0.1% Triton X-100
(Sigma). After blocking (5% BSA in PBS), the following primary anti-
bodies were applied (overnight, 4°C): affinity purified N70 (above),
plus monoclonal anti-MAP2 (Sigma), mouse polyclonal anti-GFAP
(Sigma) or monoclonal anti-neurofilament (Biogenex, San Ramon,
California). Secondary antibodies (1 h, room temperature) were either
Cy3-labeled goat-anti-rabbit (Dako, Hamburg, Germany) or Texas
Red-labeled goat-anti-rabbit (Molecular Probes) together with Cy2-
labeled goat-anti-mouse (both Dako), diluted according to the 
manufacturers’ instructions.
Determination of NMNAT activity. Mice were killed, and whole brains
were immediately removed and cut into two equal hemispheres for
NMNAT assay and NAD+ determination, respectively. Tissue was sus-
pended in 3 volumes of 100 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 1 mM
MgCl2, 1 mM DTT, 1 mM PMSF and homogenized on ice (3 × 3 s with
10-s intervals) using an Ultra-Turrax homogenizer at medium speed.
NMNAT activity was determined using a reaction mixture of 40 mM
Tris-HCl pH 7.5, 5 mM nicotinamide mononucleotide (NMN), 3.4 mM
ATP, 18 mM MgCl2, 10 mM NaF, and brain homogenate (final volume of
0.5 ml). The reaction was started by the addition of NMN at 37°C and
stopped after 10–40 min by adding 100 µl of assay mixture to 50 µl of
ice-cold 1.2 M HClO4. After 10 min, at 0°C the mixture was centrifuged
and 130 µl of supernatant was neutralized by addition of 35 µl 0.8-M
K2CO3. NMNAT activity was calculated after HPLC identification and
quantification of NAD+ produced48. One unit of enzyme activity cataly-
ses the synthesis of 1 µmol of NAD+ per minute at 37°C.
Determination of NAD+ content. A brain hemisphere in 2 volumes 7.5%
ice-cold HClO4 was homogenized using an Ultra-Turrax (4 × 4 s, with
20 s intervals). After 15 min at 0°C, the suspension was centrifuged at
16,000 g for 1 min. The pH was adjusted to 6.0 using 0.8 M K2CO3. After
centrifugation, the extract was analyzed by HPLC48.
Animal experimentation was approved by Stadt Köln Veterinäramt,
licence K13,11//00.
GenBank accession numbers. The GenBank accession number for
NMNAT is AF312734; for Wld, AF260924.
Note: Supplementary figures are available on the Nature Neuroscience web site
(http://neuroscience.nature.com/web_specials).
ACKNOWLEDGEMENTS
We thank E. Janssen, C. Hoffmann (Department of Anatomy I, University of
Cologne), F. Carnevali, F. Pierella (University of Ancona), S. Fearn and 
M. Botham (University of Southampton) for technical assistance, T. Vogt for
supplying pHβAPr-1 plasmid and R. Martini for critically reading the
manuscript. This work was supported by the Federal Ministry of Education and
Research (FKZ: 01 KS 9502) and Center for Molecular Medicine, University of
Cologne (ZMMK) (T.G.A.M., W.M., D.W., M.P.C.), a Wellcome Trust
Biomedical Collaboration Grant (R.R.R., M.P.C.) and Consiglio Nazionale delle
Ricerche Target Project “Biotechnology” (M.E., G.M.).
RECEIVED 27 SEPTEMBER; ACCEPTED 31 OCTOBER 2001
1. Waller, A. Experiments on the section of glossopharyngeal and hypoglossal
nerves of the frog and observations of the alternatives produced thereby in the
structure of their primitive fibres. Phil. Trans. R. Soc. Lond. 140, 423–429 (1850).
2. Deckwerth, T. L. & Johnson, E. M. Jr. Neurites can remain viable after
destruction of the neuronal soma by programmed cell death (apoptosis).
Dev. Biol. 165, 63–72 (1994).
3. Finn, J. T. et al. Evidence that Wallerian degeneration and localized axon
degeneration induced by local neurotrophin deprivation do not involve
caspases. J. Neurosci. 20, 1333–1341 (2000).
4. Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H. & Gordon, S. Absence of
Wallerian degeneration does not hinder regeneration in peripheral nerve.
Eur. J. Neurosci. 1, 27–33 (1989).
5. Perry, V. H., Lunn, E. R., Brown, M. C., Cahusac, S. & Gordon, S. Evidence
that the rate of Wallerian degeneration is controlled by a single autosomal
dominant gene. Eur. J. Neurosci. 2, 408–413 (1990).
6. Perry, V. H., Brown, M. C. & Lunn, E. R. Very slow retrograde and Wallerian
degeneration in the CNS of C57BL/Ola mice. Eur. J. Neurosci. 3, 102–105
(1991).
7. Glass, J. D., Brushart, T. M., George, E. B. & Griffin, J. W. Prolonged survival
of transected nerve fibres in C57BL/Ola mice is an intrinsic characteristic of
the axon. J. Neurocytol. 22, 311–321 (1993).
8. Buckmaster, E. A., Perry, V. H. & Brown, M. C. The rate of Wallerian
degeneration in cultured neurons from wild type and C57BL/WldS mice
depends on time in culture and may be extended in the presence of elevated
K+ levels. Eur. J. Neurosci. 7, 1596–1602 (1995).
9. Zhang, Z., Fujiki, M., Guth, L. & Steward, O. Genetic influences on cellular
reactions to spinal cord injury: a wound-healing response present in normal
mice is impaired in mice carrying a mutation (WldS) that causes delayed
Wallerian degeneration. J. Comp. Neurol. 371, 485–495 (1996).
10. Dal Canto, M. C. & Gurney, M. E. Neuropathological changes in two lines of
mice carrying a transgene for mutant human Cu, Zn SOD, and in mice
overexpressing wild type human SOD: a model of familial amyotrophic
lateral sclerosis (FALS). Brain Res. 676, 25–40 (1995).
11. Perry, V.H. & Anthony, D.C. Axon damage and repair in multiple sclerosis.
Phil. Trans. R. Soc. Lond. B Biol. Sci. 354, 1641–1647 (1999).
12. Glynn, P. Neural development and neurodegeneration: two faces of
neuropathy target esterase. Prog. Neurobiol. 61, 61–74 (2000).
13. Wang, M. S., Wu, Y., Culver, D. G. & Glass, J. D. The gene for slow Wallerian
degeneration (WldS) is also protective against vincristine neuropathy.
Neurobiol. Dis. 8, 155–161 (2001).
14. Sagot, Y. et al. Bcl-2 overexpression prevents motoneuron cell body loss but
not axonal degeneration in a mouse model of a neurodegenerative disease. 
J. Neurosci. 15, 7727–7733 (1995).
15. Houseweart, M. K. & Cleveland, D. W. Bcl-2 overexpression does not protect
neurons from mutant neurofilament-mediated motor neuron degeneration.
J. Neurosci. 19, 6446–6456 (1999).
16. Coleman, M. P. et al. An 85-kb tandem triplication in the slow Wallerian
degeneration (WldS) mouse. Proc. Natl. Acad. Sci. USA 95, 9985–9990 (1998).
17. Lyon, M. F., Ogunkolade, B. W., Brown, M. C., Atherton, D. J. & Perry, V. H. A
gene affecting Wallerian nerve degeneration maps distally on mouse
chromosome 4. Proc. Natl. Acad. Sci. USA 90, 9717–9720 (1993).
18. Conforti, L. et al. A Ufd2/D4Cole1e chimeric protein and overexpression of
Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc. Natl. Acad. Sci.
USA 97, 11377–11382 (2000).
19. Emanuelli, M. et al. Human NMN adenylyltransferase: molecular cloning,
chromosomal localization, tissue mRNA levels, bacterial expression, and
enzymatic properties. J. Biol. Chem. 276, 406–412 (2001).
20. Magni, G., Amici, A., Emanuelli, M., Raffaelli, N. & Ruggieri, S. Enzymology
of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73, 135–182 (1999).
21. Conforti, L. et al. The major brain isoform of Kif1b lacks the putative
mitochondria-binding domain. Mamm. Genome 10, 617–622 (1999).
22. Zhao, C. et al. Charcot-Marie-Tooth disease type 2a caused by mutation in a
microtubule motor kif1bbeta. Cell 105, 587–597 (2001).
23. Ribchester, R. R. et al. Persistence of neuromuscular junctions after axotomy
in mice with slow Wallerian degeneration (C57BL/WldS). Eur. J. Neurosci. 7,
1641–1650 (1995).
24. Gillingwater, T. H. & Ribchester, R. R. Age-dependent synapse withdrawal at
axotomised neuromuscular junctions in WldS mutant mice. J. Physiol.
(Lond.) 523P, 53P (2000). 
25. Gillingwater, T. H. & Ribchester, R. R. Compartmental neurodegeneration
and synaptic plasticity in the WldS mutant mouse. J. Physiol. (Lond.) 534,
627–639 (2001).
26. Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing
multiple spectral variants of GFP. Neuron 28, 41–51 (2000).
27. Brown, M. C., Booth, C. M., Lunn, E. R. & Perry, V. H. Delayed response to
denervation in muscles of C57BL/Ola mice. Neuroscience 43, 279–283
(1991).
28. Sagot, Y., Tan, S. A., Hammang, J. P., Aebischer, P. & Kato, A. C. GDNF slows
loss of motoneurons but not axonal degeneration or premature death of
pmn/pmn mice. J. Neurosci. 16, 2335–2341 (1996).
29. Burne, J. F., Staple, J. K. & Raff, M. C. Glial cells are increased proportionally
in transgenic optic nerves with increased numbers of axons. J. Neurosci. 16,
2064–2073 (1996).
30. Koegl, M. et al. A novel ubiquitination factor, E4, is involved in
multiubiquitin chain assembly. Cell 96, 635–644 (1999).
31. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-
terminal hydrolase in gad mice. Nat. Genet. 23, 47–51 (1999).
articles



































© 2001 Nature Publishing Group  http://neurosci.nature.com
1206 nature neuroscience  •  volume 4  no 12  •  december 2001
32. Hamilton, M. H., Tcherepanova, I., Huibregtse, J. M. & McDonnell, D. P.
Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent
degradation of its nuclear substrates. J. Biol. Chem. 276, 26324–26331 (2001).
33. Smith, S. The world according to PARP. Trends Biochem. Sci. 26, 174–179
(2001).
34. Ha, H.C. & Snyder, S.H. Poly(ADP-ribose) polymerase is a mediator of
necrotic death by ATP depletion. Proc. Natl. Acad. Sci. USA 96, 13978–13982
(1999).
35. Nagayama, T. et al. Activation of poly(ADP-ribose) polymerase in the rat
hippocampus may contribute to cellular recovery following sublethal
transient global ischemia. J. Neurochem. 74, 1636–1645 (2000).
36. Smith, K. J., Kapoor, R., Hall, S. M. & Davies, M. Electrically active axons
degenerate when exposed to nitric oxide. Ann. Neurol. 49, 470–476 (2001).
37. Di Lisa, F. & Ziegler, M. Pathophysiological relevance of mitochondria in
NAD(+) metabolism. FEBS Lett. 492, 4–8 (2001).
38. Frei, R. et al. Loss of distal axons and sensory Merkel cells and features
indicative of muscle denervation in hindlimbs of P0-deficient mice. 
J. Neurosci. 19, 6058–6067 (1999).
39. Mi, W., Conforti, L. & Coleman, M. P. Genotyping methods to detect a unique
neuroprotective factor for axons (WldS). J. Neurosci. Methods (in press).
40. Valente, E.M. et al. Localization of a novel locus for autosomal recessive early-
onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am. J. Hum.
Genet. 68, 895–900 (2001).
41. Fujiki, M., Zhang, Z., Guth, L. & Steward, O. Genetic influences on cellular
reactions to spinal cord injury: activation of macrophages/microglia and
astrocytes is delayed in mice carrying a mutation (WldS) that causes delayed
Wallerian degeneration. J. Comp. Neurol. 371, 469–484 (1996).
42. Gunning, P., Leavitt, J., Muscat, G., Ng, S. Y. & Kedes, L. A human beta-actin
expression vector system directs high-level accumulation of antisense
transcripts. Proc. Natl. Acad. Sci. USA 84, 4831–4835 (1987).
43. Karnovsky, M. J. A formaldehyde-glutaraldehyde fixative of high osmolarity
for use in electron microscopy. J. Cell Biol. 27, 137A (1965). 
44. Reynolds, E. E. The use of lead citrate at high pH as an electron opaque stain
in electron microscopy. J. Cell Biol. 17, 208 (1963).
45. Costanzo, E. M., Barry, J. A. & Ribchester, R. R. Co-regulation of synaptic
efficacy at stable polyneuronally innervated neuromuscular junctions in
reinnervated rat muscle. J. Physiol. (Lond.) 521, 365–374 (1999).
46. Costanzo, E. M., Barry, J. A. & Ribchester, R. R. Competition at silent
synapses in reinnervated skeletal muscle. Nat. Neurosci. 3, 694–700
(2000).
47. Ribchester, R. R., Mao, F. & Betz, W. J. Optical measurements of activity-
dependent membrane recycling in motor nerve terminals of mammalian
skeletal muscle. Proc. R. Soc. Lond. B Biol. Sci. 255, 61–66 (1994).
48. Balducci, E. et al. Assay methods for nicotinamide mononucleotide





































© 2001 Nature Publishing Group  http://neurosci.nature.com
